Drug intelligence / Profile preview

tetanus toxoid

Development stage: Approved
Lead developer: Sanofi Pasteur
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

**Tetanus toxoid** is a detoxified, nonpathogenic form of tetanospasmin, the neurotoxin produced by *Clostridium tetani*. It is used as an active-immunization antigen to induce toxin-neutralizing antibodies and immunologic memory that prevent tetanus; vaccine products containing tetanus toxoid are commonly adsorbed to aluminum salts and are often supplied in combination with diphtheria and/or pertussis antigens. In the United States, routine tetanus protection is generally delivered through DTaP, Tdap, or Td combination vaccines rather than monovalent tetanus-toxoid products. ([cdc.gov](https://www.cdc.gov/tetanus/vaccines/index.html))

Brand names: TDVAXTenivac
Other names: TTtetanus toxoid vaccine

Beyond the preview

Go deeper on tetanus toxoid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tetanus toxoid.

Explore the full profile